PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9125666-0	1997	Acute and chronic in vivo inhibition of angiotensin-converting enzyme by perindopril in the endothelium and adventitia of large arteries and organs of the rabbit.	Perindopril	73-84	angiotensin-converting enzyme	Oryctolagus cuniculus	40-69	
9125666-2	1997	In this study, we evaluated the acute and chronic in vivo inhibition of ACE by perindopril in both the endothelium and adventitia of large blood vessels including the aorta, carotid, and femoral arteries, heart, lung, and kidney by using in vitro autoradiography with [(125)I]351A as a ligand.	Perindopril	79-90	angiotensin-converting enzyme	Oryctolagus cuniculus	72-75	
9125666-3	1997	After short-term (0.1, 0.3, and 1 mg/kg) or long-term oral administration (0.3 mg/kg), perindopril significantly inhibited plasma ACE (p < 0.001), the plasma angiotensin II (Ang II)/Ang I ratio (p < 0.01), and decreased mean arterial pressure (p < 0.001) in a dose-related manner.	Perindopril	87-98	angiotensin-converting enzyme	Oryctolagus cuniculus	130-133	
9125666-4	1997	In the aorta, carotid, and femoral arteries, free ACE was inhibited to a similar extent in both the endothelium and adventitia by perindopril, in a dose-dependent manner, whereas total ACE in both layers of these vessels was unaltered.	Perindopril	130-141	angiotensin-converting enzyme	Oryctolagus cuniculus	50-53	
9125666-5	1997	Similar short- and long-term ACE inhibition by perindopril was observed in the lung and heart, with somewhat greater inhibition of kidney and plasma ACE.	Perindopril	47-58	angiotensin-converting enzyme	Oryctolagus cuniculus	29-32	
9125666-8	1997	These results demonstrate that perindopril readily penetrates the vascular wall after short- or long-term oral administration, and in a dose-dependent manner, potently inhibits both endothelial and advential vascular ACE to a comparable degree.	Perindopril	31-42	angiotensin-converting enzyme	Oryctolagus cuniculus	217-220